Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 6
2005 3
2006 2
2007 4
2008 2
2009 2
2010 4
2011 1
2012 3
2013 5
2014 3
2015 3
2016 2
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators. Bielack SS, et al. J Clin Oncol. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1. J Clin Oncol. 2015. PMID: 26033801 Free PMC article. Clinical Trial.
Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.
Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK; Children’s Oncology Group. Baker DL, et al. N Engl J Med. 2010 Sep 30;363(14):1313-23. doi: 10.1056/NEJMoa1001527. N Engl J Med. 2010. PMID: 20879880 Free PMC article. Clinical Trial.
Pediatric Hodgkin's disease.
Oliapuram Jose B, Koerner P, Bertolone S, Patel CC, Spanos WJ Jr, Paris KJ, Silverman CL, Yashar CM. Oliapuram Jose B, et al. Among authors: bertolone s. J Ky Med Assoc. 2004 Mar;102(3):104-6. J Ky Med Assoc. 2004. PMID: 15067795
Methylene blue reversal of ifosfamide-related encephalopathy.
Raj AB, Bertolone SJ, Jaffe N. Raj AB, et al. Among authors: bertolone sj. J Pediatr Hematol Oncol. 2004 Feb;26(2):116. doi: 10.1097/00043426-200402000-00010. J Pediatr Hematol Oncol. 2004. PMID: 14767201 No abstract available.
Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2.
Person RE, Li FQ, Duan Z, Benson KF, Wechsler J, Papadaki HA, Eliopoulos G, Kaufman C, Bertolone SJ, Nakamoto B, Papayannopoulou T, Grimes HL, Horwitz M. Person RE, et al. Among authors: bertolone sj. Nat Genet. 2003 Jul;34(3):308-12. doi: 10.1038/ng1170. Nat Genet. 2003. PMID: 12778173 Free PMC article.
43 results